Document is current

Article History

Received: 4 July 2022

Accepted: 1 August 2022

First Online: 12 August 2022

Declarations

:

: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: David AZRIA: co-founder of NovaGray (outside the field of the present article): Olivier DEREURE: investigator and/or consultant and/or member of advisory boards and/or speaker for: BMS, MSD, Sanofi Merck GmBH: Brigitte DRENO: investigator and/or consultant and/or advisory boards and/or speaker for: BMS, Regeneron, Merck: Caroline GAUDY MARQUESTE: speaker for BMS: Eve MAUBEC: consultant and/or advisory board; Sanofi, Novartis; research funding for AP-HP: MSD; Travel accommodations: Pierre Fabre, Sanofi, MSD: Nicolas MEYER: investigator and/or consultant and/or advisory boards and/or speaker for: BMS, MSD, Sanofi Merck GmBH: Nicolas MOLINARI: grants from GSK and Astra Zeneca, outside the submitted work. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

: This study has been approved by the CHU de Montpellier Institut Review Board (IRB-MTP_2020_04_202000386). No patient refused to participate in this retrospective study after an information note was sent to all of them.

: The patient pictured on Fig.  has given his written consent for publication of his photographs and associated data. No other patient is recognizable from the data presented in this article.